Acute leukaemia, Acute lymphoblastic leukaemia (ALL), Blood cancers, Children's cancers, Leukaemia
Results
Phase 2
This trial looked at dasatinib for children and young people who were newly diagnosed with acute lymphoblastic leukaemia (ALL).
It was for those whose ALL had the .
The trial was for children and young people up to and including the age of 17.
The trial was open for people to join between 2012 and 2014. The team presented results at a conference in 2017 and published results in 2023.
Recruitment start: 4 December 2012
Recruitment end: 29 May 2014
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Vaskar Saha
Bristol-Myers Squibb
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)
Last reviewed: 20 Aug 2024
CRUK internal database number: 9236